Drug Profile
Efzofitimod - aTyr Pharma
Alternative Names: ATY 1923; ATYR-1923; iMod.Fc; KRP-R120; StalarisLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator aTyr Pharma
- Developer aTyr Pharma; Foundation for Sarcoidosis Research; Kyorin Pharmaceutical
- Class Anti-inflammatories; Antifibrotics; Antirheumatics; Antivirals; Immunoglobulin Fc fragments; Proteins; Recombinant fusion proteins
- Mechanism of Action Neuropilin-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pulmonary sarcoidosis
- Phase II COVID-19 pneumonia; Interstitial lung diseases
- Preclinical Rheumatoid arthritis
- No development reported Pulmonary fibrosis
Most Recent Events
- 14 Mar 2024 aTyr Pharma announces intention to file Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis
- 14 Mar 2024 aTyr Pharma initiates an Individual Patient Expanded Access Program (EAP) for Pulmonary sarcoidosis (In adults, In the elderly, Treatment-experienced) (IV, Infusion)
- 21 Feb 2024 aTyr Pharma plans Individual Patient Expanded Access Program (EAP) for Pulmonary sarcoidosis (In adults, In the elderly, Treatment-experienced) (IV, Infusion)